BIOMAT Database Logo BIOMAT Database Logo

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. 2000

R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.

OBJECTIVE To investigate and to compare the steady-state plasma pharmacokinetics of nevirapine in a dosing regimen of 400 mg once daily versus 200 mg twice daily in HIV-1-infected individuals. METHODS Open-label, randomized, cross-over study. METHODS Twenty HIV-1-infected individuals who already used nevirapine as part of their antiretroviral regimen were randomized to continue their current regimen (200 mg twice daily) or to switch to the alternate regimen (400 mg once daily). The steady-state plasma pharmacokinetics of nevirapine were assessed after 2 weeks during a 24-h period. Subsequently, patients were switched to the alternate regimen and the pharmacokinetics of nevirapine were assessed again after 2 weeks. Non-compartmental methods were used to calculate the area under the plasma concentration versus time curve (AUC[24h]), and the maximal (Cmax) and minimal plasma concentration (Cmin), the time to Cmax (t(max)), the plasma elimination half-life (t1/2), the apparent oral clearance (Cl/F) and the apparent volume of distribution (V/F). Differences in these pharmacokinetic parameters for the two dosing regimens were tested using ANOVA. RESULTS The exposure to nevirapine, as measured by the AUC[24h], was not significantly different between the 400 mg once daily and 200 mg twice daily dosing regimen (P = 0.60). Furthermore, the values for t(max), t1/2 Cl/F and V/F were not significantly different between the two dosing regimens (P > or = 0.08). However, Cmax and Cmin were higher and lower, respectively, when nevirapine was used in the once daily regimen as compared with the twice daily regimen. The median values for Cmax and Cmin as measured for the once daily and twice daily regimens were 6.69 and 5.74 microg/ml, respectively (P = 0.03), and 2.88 and 3.73 microg/ml, respectively (P < 0.01). CONCLUSIONS These data show that the daily exposure to nevirapine, as measured by the plasma AUC[24h], is not different between a 400 mg once daily and a 200 mg twice daily dosing regimen. However, Cmax and Cmin are higher and lower, respectively, for the once daily regimen as compared with the twice daily regimen. The clinical implications of these differences remain to be established.

UI MeSH Term Description Entries
D008297 Male Males
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018592 Cross-Over Studies Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed) Cross-Over Design,Cross-Over Trials,Crossover Design,Crossover Studies,Crossover Trials,Cross Over Design,Cross Over Studies,Cross Over Trials,Cross-Over Designs,Cross-Over Study,Crossover Designs,Crossover Study,Design, Cross-Over,Design, Crossover,Designs, Cross-Over,Designs, Crossover,Studies, Cross-Over,Studies, Crossover,Study, Cross-Over,Study, Crossover,Trial, Cross-Over,Trial, Crossover,Trials, Cross-Over,Trials, Crossover

Related Publications

R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.
January 2010, HIV clinical trials,
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
October 2008, The Journal of antimicrobial chemotherapy,
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Steady-state pharmacokinetics of two sustained-release theophylline products during once-daily and twice-daily dosing.
October 1987, Clinical pharmacy,
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
December 1998, AIDS (London, England),
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
January 2005, HIV clinical trials,
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Steady-state pharmacokinetics of pefloxacin administered once and twice daily.
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
February 2006, AIDS (London, England),
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
December 2011, Journal of acquired immune deficiency syndromes (1999),
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India.
December 2007, Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002),
R P van Heeswijk, and A I Veldkamp, and J W Mulder, and P L Meenhorst, and F W Wit, and J M Lange, and S A Danner, and N A Foudraine, and M O Kwakkelstein, and P Reiss, and J H Beijnen, and R M Hoetelmans
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
January 2011, Antiviral therapy,
Copied contents to your clipboard!